Evidence map›Paper›PMID 41645221›Full record

ArticleJournal of nanobiotechnology2026

Biosynthetic OMVs with endogenous GM-CSF loading for ultrasound-triggered in situ cancer vaccination.

Rui Zhang, Beibei Zhang, Shaobo Duan, Xiaoxia Xu, Ru Jiang, Yingying Zhao, Zesheng Li, Xu Zhang, Siyi Yang, Mengmeng Sang and 4 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of nanobiotechnology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Rui ZhangZhengzhou University People's Hospital, Henan Provincial People's Hospital, Zhengzhou, 450003, China.
Beibei ZhangSchool of Biological Engineering, Henan University of Technology, Zhengzhou, 450001, China. zhangbb058@163.com.
Shaobo DuanZhengzhou University People's Hospital, Henan Provincial People's Hospital, Zhengzhou, 450003, China.
Xiaoxia XuZhengzhou University People's Hospital, Henan Provincial People's Hospital, Zhengzhou, 450003, China.
Ru JiangZhengzhou University People's Hospital, Henan Provincial People's Hospital, Zhengzhou, 450003, China.
Yingying ZhaoZhengzhou University People's Hospital, Henan Provincial People's Hospital, Zhengzhou, 450003, China.
Zesheng LiZhengzhou University People's Hospital, Henan Provincial People's Hospital, Zhengzhou, 450003, China.
Xu ZhangSchool of Biological Engineering, Henan University of Technology, Zhengzhou, 450001, China.
Siyi YangSchool of Biological Engineering, Henan University of Technology, Zhengzhou, 450001, China.
Mengmeng SangSchool of Biological Engineering, Henan University of Technology, Zhengzhou, 450001, China.
Linlin ZhangZhengzhou University People's Hospital, Henan Provincial People's Hospital, Zhengzhou, 450003, China.
Juan ZhangZhengzhou University People's Hospital, Henan Provincial People's Hospital, Zhengzhou, 450003, China.
Yongchao WangSchool of Life Sciences, Zhengzhou University, Zhengzhou, 450001, China. wangyongchao@zzu.edu.cn.
Lianzhong ZhangZhengzhou University People's Hospital, Henan Provincial People's Hospital, Zhengzhou, 450003, China. zlz8777@163.com.

Funding

Henan Province Natural Science Foundation 242300421196Henan Provincial Science and Technology Research Project 242102311104Key Research and Development Project in Henan Province 221111310400National Natural Science Foundation of China 82371987National Natural Science Foundation of China 82502382National Natural Science Foundation of China 82572400National Natural Science Foundation of Henan province 252300421151
6 · The paper itself

Abstract

Impaired dendritic cell (DC) recruitment, maturation, and antigen presentation within the immunosuppressive tumor microenvironment (TME) critically limit the efficacy of cancer immunotherapies. Strategies attempt to restore DC function using systemically administered granulocyte-macrophage colony-stimulating factor (GM-CSF) are constrained by poor tumor accumulation and dose-limiting toxicity. Herein, we developed a biosynthetic, ultrasound-triggered in situ cancer vaccine based on a hybrid nanoplatform (OMVs

Indexed as

Cancer VaccinesGranulocyte-Macrophage Colony-Stimulating FactorAnimalsAntigens, NeoplasmChlorophyllidesDendritic CellsHumansImmunotherapyLiposomesMicePorphyrinsReactive Oxygen SpeciesTumor MicroenvironmentUltrasonic WavesAntigens, NeoplasmCancer VaccinesChlorophyllidesGranulocyte-Macrophage Colony-Stimulating FactorLiposomesphytochlorinPorphyrinsReactive Oxygen SpeciesCancer immunotherapyDendritic cellsOuter membrane vesiclesPD-1 resistanceUltrasound

Identifiers

PMID41645221
PMCPMC12964811

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.